INT92138

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 2000
Last Reported 2011
Negated 0
Speculated 1
Reported most in Body
Documents 28
Total Number 29
Disease Relevance 25.64
Pain Relevance 7.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (CDKN2A) DNA binding (CDKN2A) protein complex (CDKN2A)
cytoplasm (CDKN2A) cytosol (CDKN2A) nucleolus (CDKN2A)
Anatomy Link Frequency
plasma 1
blood vessels 1
B-cell 1
GALT 1
myotubes 1
CDKN2A (Homo sapiens)
Pain Link Frequency Relevance Heat
melanocortin 1 receptor 790 99.80 Very High Very High Very High
rheumatoid arthritis 296 99.68 Very High Very High Very High
spinal inflammation 40 99.44 Very High Very High Very High
Dismenorea 7 99.00 Very High Very High Very High
Arthritis 40 98.68 Very High Very High Very High
vincristine 2 95.20 Very High Very High Very High
positron emission tomography 1 88.84 High High
Inflammatory mediators 7 84.88 Quite High
intrathecal 2 84.88 Quite High
Perioperative pain 1 84.04 Quite High
Disease Link Frequency Relevance Heat
Melanoma 770 100.00 Very High Very High Very High
Diabetes Mellitus 396 100.00 Very High Very High Very High
Acute Renal Failure 253 100.00 Very High Very High Very High
Proteinuria 67 100.00 Very High Very High Very High
Rhabdomyolysis 3 100.00 Very High Very High Very High
Carcinoma 46 99.82 Very High Very High Very High
Aneuploidy 2 99.74 Very High Very High Very High
Rheumatoid Arthritis 296 99.68 Very High Very High Very High
Low Back Pain 54 99.44 Very High Very High Very High
Cancer 254 99.26 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Genotyping of CDKN2A and MC1R
CDKN2A Binding (Genotyping) of associated with melanocortin 1 receptor
1) Confidence 0.37 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.27 Pain Relevance 0.22
Because many MC1R variants were too rare to examine their individual association with melanoma risk in CDKN2A carriers, all nonsynonymous variants were grouped in various ways to make the following comparisons¬ócarriers of any MC1R variant compared with homozygosity for the MC1R consensus sequence; carriers of multiple MC1R variants (1, ?
CDKN2A Spec (examine) Binding (association) of associated with melanocortin 1 receptor and melanoma
2) Confidence 0.37 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.43 Pain Relevance 1.02
Further investigation of the TYR and CDKN2A/MTAP loci in families segregating CDKN2A mutations will allow assessment of whether common variants of these genes also modify penetrance of CDKN2A deleterious mutations.
CDKN2A Binding (investigation) of
3) Confidence 0.37 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.76 Pain Relevance 0.37
Indeed, a molecular basis for the link between CDKN2A and MC1R has been provided by in vitro studies that showed that the increased expression of p16INK4a after exposure to ultraviolet radiation is potentiated by ?
CDKN2A Binding (link) of associated with melanocortin 1 receptor
4) Confidence 0.37 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.52 Pain Relevance 0.93
The Melanoma Genetics Consortium (GenoMEL), which includes major familial melanoma research groups from Europe, North America, and Australia, has recruited the largest sample of CDKN2A mutation carriers, to our knowledge, to assess the association of MC1R variants with melanoma risk.
CDKN2A Binding (recruited) of associated with melanocortin 1 receptor and melanoma
5) Confidence 0.37 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 1.07 Pain Relevance 0.79
Interestingly, none of the diabetes-related traits showed an association with CDKN2A/B rs10811661.
CDKN2A Binding (association) of associated with diabetes mellitus
6) Confidence 0.36 Published 2008 Journal Diabetes Section Body Doc Link PMC2551696 Disease Relevance 0.43 Pain Relevance 0
We also observed significant association between CDKN2A/B rs10811661 and type 2 diabetes and IFG with a slightly higher odds ratio (?
CDKN2A Binding (association) of associated with diabetes mellitus
7) Confidence 0.36 Published 2008 Journal Diabetes Section Body Doc Link PMC2551696 Disease Relevance 0.37 Pain Relevance 0
We found no evidence of pairwise synergistic gene-gene interactions on type 2 diabetes and the related phenotypes among CDKAL1-rs9465871, CDKN2A/B-rs10811661, IGF2BP2-rs4402960, and SLC30A8-rs13266634.
CDKN2A Binding (interactions) of associated with diabetes mellitus
8) Confidence 0.36 Published 2008 Journal Diabetes Section Body Doc Link PMC2551696 Disease Relevance 0.75 Pain Relevance 0
As noted above, in normal myotubes, CUGBP1 interacts with cyclin D3/cdk4 complex which phosphorylates CUGBP1 at Ser302 [68].
cdk4 Binding (complex) of in myotubes
9) Confidence 0.36 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.07 Pain Relevance 0
In addition, hMSH2, hMLH1, p16Ink4 and GALT genes were associated for the first time with adenomyosis and its pathogenesis.
p16Ink4 Binding (associated) of in GALT associated with dismenorea
10) Confidence 0.36 Published 2000 Journal Int. J. Mol. Med. Section Abstract Doc Link 11078826 Disease Relevance 0.76 Pain Relevance 0.53
Furthermore, despite a strong association between the CDKN2A/B SNP rs10811661 and type 2 diabetes, no association was observed with any of the diabetes-related quantitative traits.
CDKN2A Binding (association) of associated with diabetes mellitus
11) Confidence 0.36 Published 2008 Journal Diabetes Section Body Doc Link PMC2551696 Disease Relevance 0.61 Pain Relevance 0
The recent generation of mice harboring these signature genetic mutations has yielded models that closely recapitulate the histopathogenesis of the human disease with KrasG12D initiating focal PanINs that rapidly undergo multistage progression in conjunction with Ink4a/Arf or p53 mutations, resulting in invasive PDAC.
Arf Binding (conjunction) of associated with adenocarcinoma and disease
12) Confidence 0.36 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504036 Disease Relevance 1.37 Pain Relevance 0
Hand-assisted laparoscopic radical nephrectomy-associated rhabdomyolysis with ARF.
ARF Binding (nephrectomy-associated) of associated with rhabdomyolysis
13) Confidence 0.36 Published 2003 Journal Am. J. Kidney Dis. Section Title Doc Link 12500214 Disease Relevance 0.93 Pain Relevance 0.08
P16 protein is a known inhibitor of cyclin-dependent kinase 4 (CDK4) that binds to CDK4 in the G1 phase of the cell cycle to down-regulate its activity.
CDK4 Binding (binds) of
14) Confidence 0.36 Published 2007 Journal Environ Health Perspect Section Body Doc Link PMC1852665 Disease Relevance 0.38 Pain Relevance 0
Immunoreactivity for p16INK4a was restricted to the nucleus and cytoplasm of native disc cells in all disc samples investigated, with no immunopositivity observed in the matrix or blood vessels (Figure 2a, b).
p16INK4a Binding (Immunoreactivity) of in blood vessels
15) Confidence 0.35 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206356 Disease Relevance 0.08 Pain Relevance 0
Another point that should be commented on is the urgent need for a common definition of ARF, an essential instrument in comparing different epidemiological studies and for evaluating therapies during clinical trials [5].


ARF Binding (definition) of associated with acute renal failure
16) Confidence 0.35 Published 2006 Journal Crit Care Section Body Doc Link PMC1751017 Disease Relevance 1.17 Pain Relevance 0
Association of p16 and RASSF1A Methylation Status to Baseline Prognostic Factors and Adverse Events
p16 Binding (Association) of
17) Confidence 0.33 Published 2011 Journal Journal of Cancer Section Body Doc Link PMC3020361 Disease Relevance 1.06 Pain Relevance 0
Both CDKN2A and CDKN2B losses have been well documented in UC, with a CDKN2A deletion often associated with worsened outcomes [24,25].
CDKN2A Binding (associated) of associated with carcinoma
18) Confidence 0.28 Published 2010 Journal BMC Med Genomics Section Body Doc Link PMC3022544 Disease Relevance 0.23 Pain Relevance 0
Biopsy of the gastric lesion demonstrated a CD20+, diffuse large B-cell lymphoma that was immunohistochemically positive for BCL-6 and negative for p16.
p16 Binding (negative) of in B-cell associated with lymphatic system cancer
19) Confidence 0.27 Published 2009 Journal J. Neurosurg. Section Abstract Doc Link 19216652 Disease Relevance 0.57 Pain Relevance 0.39
Conversely, type II cancer is more often aneuploid and harbors alterations in CDKN2A, TP53, and ERBB2 [4].
CDKN2A Binding (alterations) of associated with aneuploidy and cancer
20) Confidence 0.27 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2913851 Disease Relevance 1.44 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox